SINOVAC BIOTECH LTD's ticker is SVA and the CUSIP is P8696W104. A total of 11 filers reported holding SINOVAC BIOTECH LTD in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $106,302 | 0.0% | 16,430 | 0.0% | 0.00% | – |
| Q2 2023 | $106,302 | +0.3% | 16,430 | 0.0% | 0.00% | – |
| Q3 2022 | $106,000 | -1.9% | 16,430 | -1.2% | 0.00% | – |
| Q2 2022 | $108,000 | -49.1% | 16,630 | -49.4% | 0.00% | – |
| Q4 2021 | $212,000 | +96.3% | 32,860 | +97.6% | 0.00% | – |
| Q3 2021 | $108,000 | +1.9% | 16,630 | +1.2% | 0.00% | – |
| Q2 2021 | $106,000 | 0.0% | 16,430 | 0.0% | 0.00% | – |
| Q1 2021 | $106,000 | -50.0% | 16,430 | -50.0% | 0.00% | – |
| Q4 2020 | $212,000 | +100.0% | 32,860 | +100.0% | 0.00% | – |
| Q3 2020 | $106,000 | 0.0% | 16,430 | 0.0% | 0.00% | – |
| Q2 2020 | $106,000 | 0.0% | 16,430 | 0.0% | 0.00% | – |
| Q1 2020 | $106,000 | 0.0% | 16,430 | 0.0% | 0.00% | – |
| Q4 2019 | $106,000 | 0.0% | 16,430 | 0.0% | 0.00% | – |
| Q3 2019 | $106,000 | -66.5% | 16,430 | -66.4% | 0.00% | – |
| Q2 2019 | $316,000 | +143.1% | 48,880 | +144.2% | 0.00% | – |
| Q1 2019 | $130,000 | -59.8% | 20,020 | -57.0% | 0.00% | – |
| Q4 2018 | $323,000 | -50.2% | 46,517 | -44.9% | 0.00% | – |
| Q3 2018 | $648,000 | -32.3% | 84,397 | -34.2% | 0.00% | – |
| Q2 2018 | $957,000 | +16.8% | 128,196 | +34.8% | 0.00% | – |
| Q1 2018 | $819,000 | +27.2% | 95,085 | +16.5% | 0.00% | – |
| Q4 2017 | $644,000 | +648.8% | 81,632 | +565.9% | 0.00% | – |
| Q3 2017 | $86,000 | -6.5% | 12,259 | -23.9% | 0.00% | – |
| Q4 2015 | $92,000 | -8.9% | 16,118 | -19.1% | 0.00% | – |
| Q3 2015 | $101,000 | -17.2% | 19,935 | -14.0% | 0.00% | – |
| Q2 2015 | $122,000 | -2.4% | 23,193 | -8.1% | 0.00% | – |
| Q1 2015 | $125,000 | +119.3% | 25,235 | +131.6% | 0.00% | – |
| Q4 2014 | $57,000 | -56.8% | 10,897 | -60.3% | 0.00% | – |
| Q3 2014 | $132,000 | -82.2% | 27,441 | -79.1% | 0.00% | – |
| Q2 2014 | $741,000 | +30.5% | 131,345 | +66.5% | 0.00% | – |
| Q1 2014 | $568,000 | +30.6% | 78,864 | +10.9% | 0.00% | – |
| Q4 2013 | $435,000 | -17.6% | 71,118 | -19.5% | 0.00% | – |
| Q3 2013 | $528,000 | +133.6% | 88,300 | +53.3% | 0.00% | – |
| Q2 2013 | $226,000 | – | 57,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 2,718,735 | $340,500,000 | 6.32% |
| Vivo Capital, LLC | 5,900,000 | $38,173,000 | 4.21% |
| Neumann Advisory Hong Kong Ltd | 315,586 | $2,042 | 0.72% |
| Yorktown Management & Research Co Inc | 74,893 | $485,000 | 0.63% |
| Skandinaviska Enskilda Banken AB (publ) | 40,000 | $259,000 | 0.00% |
| Renaissance Technologies | 2,375,841 | $1,537,000 | 0.00% |
| US BANCORP \DE\ | 127 | $0 | 0.00% |
| JPMORGAN CHASE & CO | 3,000 | $19,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 1,687 | $11,000 | 0.00% |
| STATE STREET CORP | 160,875 | $1,041,000 | 0.00% |